Perspective Therapeutics (CATX) Gross Margin (2010 - 2023)

Perspective Therapeutics has disclosed Gross Margin across 14 years of filings, most recently posting 0.8% for Q4 2023.

• Gross Margin for Q4 2023 came in at 0.8%, changed N/A year-over-year; the trailing twelve-month figure through Dec 2023 was 233.93% (changed N/A YoY), and the FY2023 annual result was 100.0%, changed N/A from the prior year.
• Gross Margin came in at 0.8% for Q4 2023 at Perspective Therapeutics, down from 33.78% in the prior quarter.
• In the past five years, Gross Margin ranged from a high of 59.24% in Q1 2020 to a low of 0.8% in Q4 2023.
• The 5-year median for Gross Margin is 45.69% (2019), against an average of 40.89%.
• Across the five-year window, Gross Margin surged 1984 bps in 2019 and sank 2291 bps in 2023, its largest moves.
• Perspective Therapeutics' Gross Margin stood at 50.36% in 2019, then slipped by 2 bps to 49.47% in 2020, then retreated by 12 bps to 43.32% in 2021, then sank by 44 bps to 24.11% in 2022, then slumped by 97 bps to 0.8% in 2023.
• The last three Gross Margin figures came in at 0.8% (Q4 2023), 33.78% (Q3 2023), and 16.53% (Q2 2023), per Business Quant data.